Work

Intranasal mRNA vaccines: Targeting mucosal immunity through optimized delivery

Year: 2025

Type: article

Abstract: The COVID-19 pandemic highlighted the transformative potential of mRNA lipid nanoparticle (LNP) vaccines, yet their limited ability to induce mucosal immunity at respiratory entry points remains a significant challenge. Intranasal vaccination offers a promising strategy to elicit local immune responses at the primary site of respiratory pathogen entry, critical for preventing infections like SARS-CoV-2 and influenza.1 In a recent study published in Molecular Therapy Nucleic Acids, Vu et al. demonstrated that while intranasal mRNA-LNPs efficiently transfect lung epithelial and immune cells, they fail to generate robust primary mucosal immunity, despite the success of LNPs in intramuscular applications, unless boosted in a primed context2 (Figure 1).

Source: Molecular Therapy — Nucleic Acids

DOI: 10.1016/j.omtn.2025.102654

Authors: Achyut Pandey, Sacheen Kumar, Shruti Mishra

Institution: Galgotias University

Language: English

Topic: RNA Interference and Gene Delivery

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900